New approaches to the endocrine prevention and treatment of breast cancer.
AffiliationCRUK Department of Medical Oncology, Christie Hospital NHS Trust, University of Manchester, Wilmslow Road, M20 4BX, Manchester, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractAll major endocrine prevention approaches act via the estrogen receptor (ER). A simple hypothesis concerning ER expression and breast cancer risk is outlined. We review breast cancer prevention trials with tamoxifen, raloxifene, aromatase inhibitors, and ovarian suppression. Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed.
CitationNew approaches to the endocrine prevention and treatment of breast cancer. 2003, 52 Suppl 1:S39-44 Cancer Chemother. Pharmacol.
JournalCancer Chemotherapy and Pharmacology
- The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
- Authors: Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, Secrest RJ
- Issue date: 2004
- Breast cancer prevention with selective estrogen receptor modulators: a perspective.
- Authors: Pritchard KI
- Issue date: 2001 Dec
- Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
- Authors: Park WC, Jordan VC
- Issue date: 2002 Feb
- Therapeutic targeting in the estrogen receptor hormonal pathway.
- Authors: Katzenellenbogen BS, Frasor J
- Issue date: 2004 Feb
- Tamoxifen to raloxifene and beyond.
- Authors: O'Regan RM, Jordan VC
- Issue date: 2001 Jun